A framework for assessment in oncology rehabilitation

Physical Therapy

Volumn 89, Issue 3, 2009, Pages 286-306

  Gilchrist, Laura S ^a,b   Galantino, Mary Lou ^c,d   Wampler, Meredith ^e   Marchese, Victoria G ^f,g   Morris, G Stephen ^h   Ness, Kirsten K ⁱ  

^a ST CATHERINE UNIVERSITY   (United States)

^b Children's Hospitals   (United States)

^c RICHARD STOCKTON COLLEGE OF NEW JERSEY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Harrison Medical Center   (United States)

^f LEBANON VALLEY COLLEGE   (United States)

^g PENN STATE COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL THERAPY MODALITIES; VOCABULARY, CONTROLLED;

EID: 61849100001     PISSN: 00319023     EISSN: None     Source Type: Journal    
DOI: 10.2522/ptj.20070309     Document Type: Review

References (253)

1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Available at: http://seer.cancer.gov/csr/1975-2005/. Accessed July 1, 2008, based on November 2007 SEER data submission, posted to the SEER Web site, 2008.
2. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2004. Incidence and mortality Web- based report. Available at: www.cdc.gov/uscs. Accessed November 26, 2008.
3. Robison LL. Cancer survivorship: unique opportunities for research. Cancer Epidemiol Biomarkers Prev. 2004; 13:1093
4. Merchant TE. Current management of childhood ependymoma. Oncology (Willison Park). 2002;16:629-642, 644; discussion 645-646, 648.
5. van den Berg H. Biology and therapy of malignant solid tumors in childhood. Cancer Chemother Biol Response Modif. 2003;21:683-707.
6. Sklar CA. Childhood brain tumors. J Pediatr Endocrinol Metab. 2002; 15:669- 673
7. Freeman CR, Taylor RE, Kortmann RD, Carrie C. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Med Pediatr Oncol. 2002;39: 99-108.
8. Habrand JL, De Crevoisier R. Radiation therapy in the management of childhood brain tumors. Childs Nerv Syst. 2001;17:121-133.
9. Kalapurakal JA, Dome JS, Perlman EJ, et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol. 2004;5:37-46.
10. Schwartz CL. Health status of childhood cancer survivors: cure is more than the eradication of cancer. JAMA. 2003;290: 1641-1643.
11. Schwartz CL. The management of Hodgkin disease in the young child. Curr Opin Pediatr. 2003;15:10-16.
12. Alcoser PW, Rodgers C. Treatment strategies in childhood cancer. J Pediatr Nurs. 2003;18:103-112.
13. Rao BN, Rodriguez-Galindo C. Local control in childhood extremity sarcomas, salvaging limbs and sparing function. Med Pediatr Oncol. 2003;41:584-587.
14. Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev. 2004;30:269-280.
15. Rutqvist LE, Rose C, Cavallin-Stahl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol. 2003;42:532-545.
16. Yeh E. Cardiotoxicity induced by chemotherapy and antibody therapy. Ann Rev Med. 2006:485-498.
17. Sklar CA, LaQuaglia MP. The long-term complications of chemotherapy in childhood genitourinary tumors. Urol Clin North Am. 2000;27:563-568.
18. Marina N. Long-term survivors of childhood cancer: the medical consequences of cure. Pediatr Clin North Am. 1997; 44:1021-1042.
19. Dieckmann K, Widder J, Potter R. Long-term side effects of radiotherapy in survivors of childhood cancer. Front Radiat Ther Oncol. 2002;37:57-68.
20. Oeffmger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582.
21. Lee JQ, Simmonds MJ, Wang XS, Novy DM. Differences in physical performance between men and women with and without lymphoma. Arch Phys Med Rehabil. 2003;84:1747-1752.
22. Oeffmger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med. 2004;2:61-70.
23. Oeffmger KC, Eshelman DA, Tomlinson GE, et al. Providing primary care for long-term survivors of childhood acute lymphoblastic leukemia. J Fam Pract. 2000;49:1133-1146.
24. International Classification of Functioning, Disability and Health: ICF. Geneva, Switzerland: World Health Organization; 2001.
25. American Physical Therapy Association. APTA Endorses ICF Model. PT Bulletin. Vol 9, issue 26, 2008. Available at: http://www.apta.org/AM/ Template.cfm?fSection=Archives2&Template=/Customsource/TaggedPage/PTIssue. cfm&Issue=06/17/ 2008#article49312.
26. Nagi S. A study in the evaluation of disability and rehabilitation potential: concepts, methods, and procedures. Am J Public Health Nations Health. 1964;54: 1568-1579.
27. Nagi S. Some Conceptual Issues in Disability and Rehabilitation. Washington, DC: American Sociological Association; 1965.
28. Jette AM. Toward a common language for function, disability, and health. Phys Ther. 2006;86:726-734.
29. Nagi SZ. An epidemiology of disability among adults in the United States. Mil- bank Mem Fund Q Health Soc. 1976;54:439-467.
30. Nagi SZ. Congruency in medical and self- assessment of disability. IMS Ind Med Surg. 1969;38:27-36.
31. Quasthoff S, Hartung HP. Chemotherapy- induced peripheral neuropathy. J Neurol. 2002;249:9-17.
32. Kesselring J, Coenen M, Cieza A, et al. Developing the ICF Core Sets for multiple sclerosis to specify functioning. Mult Scler. 2008;14:252-254.
33. Geyh S, Cieza A, Schouten J, et al. ICF Core Sets for stroke. J Rehabil Med. 2004:135-141.
34. Starrost K, Geyh S, Trautwein A, et al. Interrater reliability of the extended ICF Core Set for stroke applied by physical therapists. Phys Ther. 2008;88:841-851.
35. Dreinhofer K, Stucki G, Ewert T, et al. ICF Core Sets for osteoarthritis. J Rehabil Med. 2004:75-80.
36. Ruof J, Cieza A, Wolff B, et al. ICF Core Sets for diabetes mellitus. J Rehabil Med. 2004:100-106.
37. Cieza A, Stucki G, Weigl M, et al. ICF Core Sets for low back pain. J Rehabil Med. 2004:69-74.
38. Stucki A, Daansen P, Fuessl M, et al. ICF Core Sets for obesity. J Rehabil Med. 2004:107-113
39. Cieza A, Schwarzkopf S, Sigl T, et al. ICF Core Sets for osteoporosis. J Rehabil Med. 2004:81-86.
40. Kirchberger I, Glaessel A, Stucki G, Cieza A. Validation of the comprehensive International Classification of Functioning, Disability and Health Core Set for rheumatoid arthritis: the perspective of physical therapists. Phys Ther. 2007;87:368-384.
41. Uhlig T, Lillemo S, Moe RH, et al. Reliability of the ICF Core Set for rheumatoid arthritis. Ann Rheum Dis. 2007,66: 1078-1084.
42. Stamm T, Geyh S, Cieza A, et al. Measuring functioning in patients with hand osteoarthritis: content comparison of questionnaires based on the International Classification of Functioning, Disability and Health (ICF). Rheumatology (Oxford). 2006;45:1534-1541.
43. Stucki A, Borchers M, Stucki G, et al. Content comparison of health status measures for obesity based on the International Classification of Functioning, Disability and Health. Int J Obes (Lond). 2006;30:1791-1799.
44. Sigl T, Cieza A, Brockow T, et al. Content comparison of low back pain-specific measures based on the International Classification of Functioning, Disability and Health (ICF). Clin f Pain. 2006;22:147-153.
45. Borchers M, Cieza A, Sigl T, et al. Content comparison of osteoporosis-targeted health status measures in relation to the International Classification of Functioning, Disability and Health (ICF). Clin Rheumatol. 2005;24:139-144.
46. Cieza A, Geyh S, Chatterji S, et al. ICF linking rules: an update based on lessons learned. J Rehabil Med. 2005;37:212-218.
47. Tschiesner U, Cieza A, Rogers SN, et al. Developing core sets for patients with head and neck cancer based on the International Classification of Functioning, Disability and Health (ICF). Eur Arch Otorhinolaryngol. 2007;264: 1215-1222.
48. Brach M, Cieza A, Stucki G. et al. ICF Core Sets for breast cancer. J Rehabil Med. 2004:121-127.
49. Stucki G, Melvin J. The International Classification of Functioning, Disability and Health: a unifying model for the conceptual description of physical and rehabilitation medicine. J Rehabil Med. 2007;39:286-292.
50. Finger ME, Cieza A, Stoll J, et al. Identification of intervention categories for physical therapy, based on the International Classification of Functioning, Disability and Health, a Delphi exercise. Phys Ther. 2006;86:1203-1220.
51. Roach K. Measurement of health outcomes:reliability, validity and responsiveness. J Prosth Orthot. 2006;18:8-12.
52. Keith R, Granger C, Hamilton B, Sherwin F. The Functional Independence Measure: a new tool for rehabilitation. In: Eisenberg M, Grzesiak R, eds. Advances in Clinical Rehabilitation. New York, NY: Springer Publishing Co; 1987:6-18.
53. Portney L, Watkins M. Foundations of Clinical Research Applications to Practice. 2nd ed. Upper Saddle River. NJ: Prentice Hall Health; 2000.
54. Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3: S84-S90.
55. Barton D, Loprinizi C. Novel approaches to reventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer. 2002;3:S121-S127.
56. Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955-969.
57. Dam FV, Schagen S, Muller M, et al. Impairment of cognitive function in women receiving adjuvant treatment for high- risk breast cancer: high-dose versus standard-dose chemotherapy. J Nat Cancer Inst. 1998;90:210-218.
58. Freeman J, Broshek D. Assessing cognitive dysfunction in breast cancer: What are the tools? Clin Breast Cancer Suppl. 2002;3:91-99.
59. Olin J. Cognitive function after systemic therapy for breast cancer. Oncology. 2001;15:613-618.
60. Rugo H, Ahles T. The impact of adjuvant therapy for hreast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003; 30:749-762.
61. Schagen S, Van Dam F. Muller M, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640-650.
62. Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76-89.
63. Tchen N, Juffs H, Downie F, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21:4175-4183.
64. Wefel J, Lenxi R, Theriault R, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292-2299.
65. Wieneke M, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61-66.
66. Paganini-Hill A, Clark L. Preliminary assessment of cognitive function in hreast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165-176.
67. Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long- term survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485-493
68. O'Shaughnessy J. Chemotherapy-related cognitive dysfunction in breast cancer. Semin Oncol Nurs. 2003;19:17-24.
69. O'Shaughnessy J. Chemotherapy-related cognitive dysfunction: a clearer picture. Clin Breast Cancer. 2003;4(suppl 2): S89-S84.
70. Folstein M, Folstein S, McHugh P. Mini- Mental State: a practical method for grading the state of patients for the clinician J Psychiatr Res. 1975; 12:189-198.
71. Jansen C, Miaskowski C, Dodd M, Dowling G. A meta-analysis of the sensitivity of various neuropsychological tests uses to detect chemotherapay-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum. 2007;34: 997-1005.
72. Cella D, Tross S, Orov E, et al. Mood states of patients after the diagnosis of cancer. J Psychosoc Oncol. 1989;7:45-53.
73. McNair D, Loor M, Droppleman L. Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service; 1971.
74. Sergi B, Ferraresi A, Troiani D, et al. Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage. Hear Res. 2003;182:56-64.
75. FDA-Approved Label for Cisplatin. 2007. Available at: http://www.fda.gov/cder/ogd/rld/18057s68.pdf. Accessed November 26, 2008.
76. Verstappen CCP, Hermans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer. Drugs. 2003;63:1549-1563
77. Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35:304-311
78. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006;11:135-141.
79. Wampler M, Miaskowski C, Hamel K, et al. The modified Total Neuropathy Score: a clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. J Support Oncol. 2006;4:397-402.
80. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology: 2003;60:337-340.
81. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;6l: 1297-1300.
82. Stevens P, Dibhle S, Miaskowski C. Prevalence, characteristics, and impact of postmastectomy pain syndrome: an in vestigation of women's experiences. Pain. 1995;61:61-68.
83. GaleckiJ, Hicer-Grzenkowicz J, Grudzien Kowalska M, et al. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer: a review. Acta Oncol. 2006;45:280-284.
84. Cherny N. The management of cancer pain. CA Cancer J Clin. 2000;50:70-116
85. Serlin R, Mendoza T, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;6l:277-284.
86. Jensen M, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986:27:117-126.
87. Jensen M, Turner J, Romano J, Fisher L. Comparative reliability and validity of chronic pain intensity measures. Pain. 1999;83:157-162.
88. Cleeland C. Measurement and prevalence of pain in cancer. Semin Oncol Nurs. 1985;1:87-92.
89. Evans C, Trudeau E, Mertzanis P, et al. Development and validation of the Pain Treatment Satisfaction Scale (PTSS): a patient satisfaction questionnaire for use in patients with chronic or acute pain. Pain. 2004;112:254-266.
90. Rietman JS, Dijkstra PU, Geertzen JH, et al. Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast carcinoma. Cancer. 2003;98:690-696.
91. Blomqvist L, Stark B, Engler N, Malm M. Evaluation of arm and shoulder mohility and strength after modified radical mastectomy and radiotherapy. Acta Oncol. 2004;43:280-283.
92. Dijkstra PU, van Wilgen PC, Buijs RP, et al. Incience of shoulder pain after neck dissection: a clinical explorative study for risk factors. Head Neck. 2001; 23:947-953.
93. Erisen L, Basel B, Irdesel J, et al. Shoulder function after accessory nerve-sparing neck dissections. Head Neck. 2004;26:967-971.
94. Guldiken Y, Orhan KS, Demirel T, et al. Assessment of shoulder impairment after functional neck dissection: long term results. Amis Nasus Larynx. 2005;32: 387-391.
95. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002; 52:72-91.
96. Owczarek J, Jasinska M, Orszulak- Michalak D. Drug-induced myopathies: an overview of possible mechanisms. Pharmacol Rep. 2005;57:23-34.
97. Mathiowetz V, Kashman N, Volland G, et al. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil. 1985;66:69-72.
98. Bohannon RW. Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years. Arch Phys Med Rehabil. 1997;78:26-32.
99. Ochs BG, Simank HG, Kopp-Schneider A, et al. Gait analysis in limb preserving tumour surgery: kinematic gait patterns after resection of malignant bone tumours near the knee joint. Z Orthop Unfall. 2007;145:763-771.
100. Benedetti MG, Catani F, Donati D, et al. Muscle performance about the knee joint in patients who had distal femoral replacement after resection of a bone tumor: an objective study with use of gait analysis. J Bone Joint Surg Am. 2000; 82:1619-1625.
101. Gerber L, Hoffman K, Chaudry U, et al. Functional outcomes and life satisfaction in long-term survivors of pediatric sarcoma. Arch Phys Med Rehabil. 2006; 87:1611-1617.
102. Choy N, Johnson N, Treleaven J, et al. Balance, mobility and gaze stability deficits remain following surgical removal of vestibular schwannoma (acoustic neuroma): an observational study Aust J Physiother. 2006;52:211-216.
103. Syczewska M, Dembowska-Baginska B, Perek-Polnik M, Perek D. Functional status of children after treatment for a malignant tumor of the CNS: a preliminary report. Gait Posture. 2006;23:206-210
104. Wampler MA, Topp KS, Miaskowski C, et al. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil, 2007;88:1002-1008.
105. Holley S. A look at the problem of falls among people with cancer. Clin J Oncol Nurs. 2002;6:193-197.
106. Camp-Sorrell D. Cardiorespiratory effects in cancer survivors. Am J Nurs. 2006; 106:55-59.
107. Floyd J, Nguyen D, Lobins R, et al. Cardiotoxicity of cancer therapy.J Clin Oncol. 2005;23:7685-7696.
108. Harris E, Correa C, Hwang W, et al. Late cardiac mortality and morbidity in early- stage breast cancer patients after breast conservation treatment. J Clin Oncol. 2006;24:4100-4106.
109. Limper A. Chemotherapy induced lung disease. Clin Chest Med. 2004;25:53-64.
110. Butland R, Pang J, Gross E, et al. Two-, six-, and twelve-minute walking tests in respiratory disease. BMJ. 1982,284:1607-1608.
111. Medical Research Council. Instructions for Use of the Questionaire on Respiratory Symptoms. Dawlish, England; WJ Holman; 1966.
112. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;4:377-381.
113. Dimeo F, Schmittel A, Fietz T, et al. Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. Ann Oncol. 2004;15:1237-1242.
114. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2008: CD006145.
115. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage. 2003;26:1049-1054.
116. Mulrooney DA, Ness KK, Neglia JP, et al. Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS). Sleep. 2008;31:271-281.
117. Taylor R, Jayasinghe UW, Koelmeyer L, et al. Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther. 2006;86:205-214.
118. Karges JR, Mark BE, Stikeleather SJ, Worrell TW. Concurrent validity of upper- extremity volume estimates: comparison of calculated volume derived from girth measurements and water displacement volume. Phys Ther. 2003;83:134-145.
119. Megens AM, Harris SR, Kim-Sing C, Mc- Kenzie DC. Measurement of upper extremity volume in women after axillary dissection for breast cancer. Arch Phys Med Rehabil. 2001;82:1639-1644.
120. Stout-Gerich NL, Pfalzer LA, McGarvey C, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer Invest. 2008;112:2809-2019.
121. Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE v3.0). Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed March 14, 2007.
122. Jaeckle KA. Neurological manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol. 2004;24:385-393.
123. Lowey SE. Spinal cord compression: an oncologic emergency associated with metastatic cancer: evaluation and management for the home health clinician. Home Healthc Nurse. 2006;24:439-446.
124. Hipp J, Springfield D, Hayes W. Predicting pathologic fracture risk in the management of metastatic bone defects. Clin Orthop Relat Res. 1995:120-135.
125. Rades D, Veninga T, Stalpers L, et al. Improved posttreatment functional outcomes is associated with better survival in patients irradiated for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2007;67:1506-1509.
126. Majhail N, Ness K, Burns L, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma: a report from the Bone Marrow Transplant Survivor Study. Biol Blood Marrow Transplant. 2007; 13:1153-1159.
127. Friedrich R, Blake F. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients. Anticancer Res. 2007,27:1841-1845.
128. Marchese VG, Connolly B, Able C, et al. Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia. Phys Ther. 2008;88: 341-350.
129. Goodman C, Snyder T. Differential Diagnosis for Physical Therapists. 4th ed. St Louis, MO: Elsevier; 2007.
130. Piech D, Sanders B, Ghazinouri R, et al. Lab values interpretation resources. Available at: http://www.acutept.org/labvalues.pdf. Accessed October 2, 2008.
131. Perenboom RJ, Chorus AM. Measuring participation according to the International Classification of Functioning, Disability and Health (ICF). Disability Rehabil. 2003;25:577-587.
132. Badley EM. Enhancing the conceptual clarity of the activity and participation components of the International Classification of Functioning, Disability and Health. Soc Sci Med. 2008;66:2335-2345.
133. Marchese VG, Rai SN, Carlson CA, et al. Assessing functional mobility in survivors of lower-extremity sarcoma: reliability and validity of a new assessment tool. Pediatr Blood Cancer. 2007;49:183-189.
134. Davis AM, Sennik S, Griffin AM, et al. Predictors of functional outcomes following limb salvage surgery for lower-extremity soft tissue sarcoma. J Surg Oncol. 2000;73:206-211.
135. Davis AM, Wright JG, Williams JI, et al. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res. 1996;5: 508-516.
136. Montoya M, Fossella F, Palmer J, et al. Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report. J Palliat Med. 2006; 9:309-316.
137. Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer f Clin. 2007;57:278-300.
138. Hwang SC, Scot CB, Chang VT, et al. Predition of survival for advanced cancer patients by recursive portioning analysis: role of Karnofsky performance status, quality of life and symptom distress. Cancer Invest 2004;22:678-687.
139. Hassan SJ, Weymuller EA Jr. Assessments of quality of life in head and neck cancer. Head Neck. 1993;15:485-496.
140. Kassa T, Wessel J. The Edmonton Functional Assessment Tool: further development and validation for use in palliative care J Palliat Care. 2001;17:5-11.
141. Mahoney F, Barthel D. Functional evaluation: the Barthel Index. MD State Med J. 1965;14:61-65.
142. Larson S, Lakin K, Anderson L, et al. Prevalence of mental retardation and developmental disabilities: estimates from the 1994/1995 national health interview survey disability supplements. Am J Merit Retard. 2001;106:231-252.
143. Lenze E, Rogers J, Martire L, et al. The association of late-life depression and anxiety with physical disability: a review of the literature and prospectus for future research. Am J Geriatr Psychiatry. 2001;9:113-135.
144. Ness K, Mertens A, Hudson M, et al. Limitations on physical performance and daily activities among long-term survivors of childhood cancer. Ann Int Med. 2006;143:639-647.
145. Wood-Dauphinée SL, Opzoomer M, Williams J, et al. Assessment of global function: the Reintegration to Normal Living Index. Arch Phys Med Rehabil. 1988; 69:583-590.
146. Schreiber D, Bell R, Wunder J, et al. Evaluating function and health-related quality of life in patients treated for extremity soft tissue sarcoma. Qual Life Res. 2006;15:1439-1446.
147. Tunn PU, Pomraenke D, Goerling U, Hohenberger P. Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours: a comparative analysis using the MSTS score, the TESS and the RNL index. Int Orthop. 2008; 32:619-625.
148. Faust D, Fogel BS. The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis. 1989:177:25-31.
149. Shilling V, Jenkins V. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176:2443-2447.
150. Meyers CA, Wefel JS. The Use of the Mini- Mental State Examination to Assess Cognitive Functioning in Cancer Trials: No Ifs, Ands, Buts, or Sensitivity. J Clin Oncol. 2003:21:3557-3558.
151. Jacobs SR, Jacobsen PB, Booth-Jones M, et al. Evaluation of the Functional Assessment of Cancer Therapy Cognitive Scale with hematopoetic stem cell transplant patients. J Pain Symptom Manage. 2007:33:13-23.
152. Galantino M, Brown D, Stricker C, Farrar J. Development and testing of a cancer cognition questionnaire. Rehab Oncol. 2006;24:15-22.
153. Ahles T, Silberfarb P, Herndon Jn, et al. Psychological adjustment of survivors of localised prostate cancer: investigating the role of dyadic adjustment, cognitive appraisal and coping style, Psychooncology. 2007;16:994-1002.
154. Brown P, Clark M, Atherton P, et al. Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer? Am J Clin Oncol. 2006;29:52-58.
155. Hack T, Degner L. Coping responses following breast cancer diagnosis predict psychological adjustment three years later. Psychooncology. 2004;13:235-247.
156. Brezden C, Phillips K, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695-2701.
157. Ahles T, Silberfarb P, Herndon J, et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol. 1998; 16:1954-1960.
158. Kurnatowski P, Putyhski L, Piotrowski S. The evaluation of certain psychological indices concerning cognitive and emotional behaviors in patients after radical neck dissection. Otolaryngol Pol. 1997; 51:58-63.
159. Jacobson G, Newman C, Hunter L, Balzer G. Balance function test correlates of the Dizziness Handicap Inventory. J Am Acad Audiol. 1991;2:253-260.
160. Humphriss R, Baguley D, Moffat D. Change in dizziness handicap after vestibular schwannoma excision. Otol Neurotol. 2003;24:661-665.
161. Enticott J, O'Leary S, Briggs R. Effects of vestibulo-ocular reflex exercises on vestibular compensation after vestibular schwannoma surgery. Otol Neurotol. 2005:26:265-269.
162. Roberts RA, Gans RE, Johnson EL, Chisolm TH. Computerized dynamic visual acuity with volitional head movement in patients with vestibular dysfunction. Ann Otol Rhinol Laryngol. 2006; 115:658-666.
163. Goebel JA, Tungsiripat N, Sinks B, Carmody J. Gaze stabilization test: a new clinical test of unilateral vestibular dysfunction. Otol Neurotol. 2007;28:68-73.
164. Shy ME, Frohman EM, So YT, et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;60:898-904.
165. Bloom S, Till S, Sonksen P, Smith S. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. Br Med J (Clin Res Ed). 1984;288:1793-1795.
166. Scott J, Huskisson E. Graphic representation of pain. Pain. 1976;2:175-184.
167. Camps C, Caballero C, Blasco A, et al. Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: efficacy and tolerability. Anticancer Res. 2005;25:46l1-4614.
168. Zernikow B, Meyerhoff U, Michel E, et al. Pain in pediatric oncology: children's and parents' perspectives. Eur J Pain. 2005;9:395-406.
169. Zernikow B, Smale H, Michel E, et al. Paediatric cancer pain management using the WHO analgesic ladder: results of a prospective analysis from 2,265 treatment days during a quality improvement study. Eur J Pain. 2006;10:587-595.
170. Villars P, Dodd M, West C, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain, J Pain Symptom Manage. 2007;33:67-77.
171. Hicks C, von Bayer C, Spafford P, et al. The faces pain scale-revised:toward a common metric in pediatric pain measurement. Pain. 2001;93:173-183.
172. Caraceni A, Portenoy R; a working group of the IASP Task Force on Cancer Pain. An international survey of cancer pain characteristics and syndromes. Pain. 1999;82:263-274.
173. Borden L, Clark P, Lovato J, et al. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer. 2006; 107:1093-1100.
174. Miaskowski C, Dodd M, West C, et al. The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management. Pain. 2007;129:55-63.
175. Joint Motion: Method of Measuring and Recording. Chicago, 1L: American Academy of Orthopaedic Surgeons; 1965.
176. Reese N, Bandy W. Joint Range of Motion and Muscle Length Testing. Philadelphia, PA: WB Saunders Co; 2002.
177. Leidenius M, Leppanen E, Krogerus L, von Smitten K. Motion restriction and axillary web syndrome after sentinel node biopsy and axillary clearance in breast cancer. Am J Surg. 2003;185: 127-130.
178. Marchese VG, Chiarello L. Relationships between specific measures of body function, activity, and participation in children with acute lymphoblastic leukemia. Rehabil Oncol. 2004;22:5-9.
179. Paulino A. Late effects of radiotherapy for pediatric extremity sarcomas. Int J Rad Oncol Biol Phys. 2004;60:265-274.
180. Golding L, Myers C, Sinning W. Y's Way to Physical Fitness. Champaign, IL: Human Kinetics Inc; 1989.
181. Kolden G, Straiam T, Ward A, et al. A pilot study of group exercise training for women with primary breast cancer: feasibility and health benefits. Psychooncology. 2006;11:447-456.
182. Ness KK, Baker KS, Dengel D, et al. Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;49: 975-981.
183. Hayes S, Battistutta D, Newman B. Objective and subjective upper body function six months following diagnosis of breast cancer. Breast Cancer Res Treat. 2005; 94:1-10.
184. Rietman J, Geertzen J, Hoekstra H, et al. Long-term treatment-related upper limb morbidity and quality of life after sentinal lymph node biopsy for stage I or II breast cancer. Eur J Surq Oncol. 2006;32: 148-152.
185. Siegel AB, Lachs M, Coleman M, Leonard JP. Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clin Lymphoma Myeloma. 2006;7:65-69.
186. Abu-Rustum N, Alektiar K, Iasonos A, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol. 2006;103:714-718.
187. Monsell EM, Furman JM, Herdman SJ, et al. Computerized dynamic platform posturography. Otolaryngol Head Neck Surg. 1997;117:394-398.
188. Gouveris H, Akkafa S, Lippold R, Mann W. Influence of nerve of origin and tumor size of vestibular schwannoma on dynamic posturography findings. Acta Otolaryngol. 2006;126:1281-1285.
189. Bergson E, Sataloff R. Preoperative computerized dynamic posturography as a prognostic indicator of balance function in patients with acoustic neuroma. Ear Nose Throat J. 2005;84:154-156.
190. Galvao D, Nosaka K, Taaffe D, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38:2045-2052.
191. Konczak J, Schoch B, Dimitrova A, et al. Functional recovery of children and adolescents after cerebellar tumour resection. Brain. 2005;128:1428-1441.
192. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
193. de Miguel Sanchez C, Elustondo S, Estirado A, et al. Palliative performance status, heart rate and respiratory rate as predictive factors of survival time in terminally ill cancer patients. J Pain Symptom Manage. 2006;31:485-492.
194. Haddy T, Mosher R, Reaman G. Hypertension and pre-hypertension in long- term survivors of childhood and adolescent cancer. Pediatr Blood Cancer. 2007;49:79-83.
195. Kourti M, Tragiannidis A, Makedou A, et al. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol Oncol. 2005;27:499-501.
196. Sagstuen H, Aass N, Fossa S, et al. Blood pressure and body mass index in long- term survivors of testicular cancer.J Clin Oncol. 2005;23:4980-4990.
197. Pietila S, Ala-Houhala M, Lenko H, et al. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment. Pediatr Blood Cancer. 2005;44: 363-369.
198. Dudgeon D, Lertzman M, Askew G. Physiologic changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage. 2001;21:373-379.
199. Nomori H, Watanabe K, Ohtsuka T, et al. Six-minute walk and pulmonary function test outcomes during the early period after lung cancer surgery with special reference to patients with chronic obstructive pulmonary disease. Jpn J Thorac Cardiovasc Surg. 2004;52:113-119.
200. Weiner D, Maity A, Carlson C, Ginsberg J. Pulmonary function abnormalities in children treated with whole lung irradiation. Pediatr Blood Cancer. 2006;46:222-227.
201. Bossi G, Cerveri I, Volpini E. et al. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann Oncol. 1997;8:19-24.
202. Herrero F, San Juan A, Fleck S, et al. Effects of detraining on the functional capacity of previously trained breast cancer survivors, Int J Sports Med. 2007;28: 257-264.
203. Herrero F, San Juan A, Fleck S, et al. Combined aerobic and resistance training in breast cancer survivors: a randomized, controlled pilot trial. Int J Sports Med. 2006;27:573-580.
204. Cheema B, Gaul C. Full-body exercise training improves fitness and quality of life in survivors of breast cancer. J Strength Cond Res. 2006;20:14-21.
205. Hlatky M, Boineau R, Higginbotham M, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64:651-654.
206. Health Related Physical Fitness; Test Manual. Reston, VA: American Alliance for Health, Physical Education, Recreation and Dance; 1980.
207. Marchese V, Ogle S, Womer R, et al. An examination of outcome measures to asess functional mobility in childhood survivors of osteosarcoma, Pediatr Blood Cancer. 2004;42:41-45.
208. Smets E, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315-325.
209. Jereczek-Fossa B, Santoro L, Alterio D, et al. Fatigue during head-and-neck radiotherapy; prospective study on 117 consecutive patients. Int J Radiat Oncol Biol Phys. 2007;68:403-415.
210. Yellen S, Cella D, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system, J Pain Symptom Manage. 1997;13:63-74.
211. Piper B, Dibble S, Dodd M, et al. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum. 1998;25:677-684.
212. Meeske K, Siegel S, Globe D, et al. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol. 2005;23:5501-5510.
213. Berger A, Farr L, Kuhn B, et al. Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage. 2007;33:398-409.
214. Mendoza T, Wang X, Cleeland C, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
215. Wang X, Giralt S, Mendoza T, et al. Clinical factors associated with cancer- related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:1319-1328.
216. Wang X, Janjan N, Guo H, et al. Fatigue during preoperative chemoradiation for resectable rectal cancer. Cancer. 2001: 92:1725-1732.
217. Stanton AW, Northfield JW, Holroyd B, et al. Validation of an optoelectric limb volumeter (Perometer). Lymphology. 1991;50:11-91.
218. Ratliff J, Cooper P. Metastatic spine tumors. South Med J. 2004;97:246-253.
219. Maniadaki I, Stiakaki E, Germankis I, Kalmanti M. Evaluation of bone mineral density at different phases of therapy for childhood ALL. Pediatr Hematol Oncol. 2006;23:11-18.
220. Karavatas SG, Reicherter A, White N, Strong A. Physical therapy management of patients with multiple myeloma: musculoskeletal considerations. Rehab Oncol. 2006;24:11-16.
221. Dimeo F, Tilmann M, Bertz H, et al. Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer. 1997;79:1717-1722.
222. Elbl L, Vasova I, Krai Z, et al. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens. J Chemother. 2006;18:199-208.
223. Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overex-pressed/amplified breast cancer, J Clin Oncol. 2008;26:1216-1222.
224. Whitney SL, Wrisley DM, Marchetti GF, et al. Clinical measurement of sit-to-stand performance in people with balance disorders: validity of data for the Five-Times- Sit-to-Stand Test. Phys Ther. 2005;85:1034-1045.
225. Duncan P, Weiner D, Chandler J, Studen- ski S. Functional reach: a new clinical measure of balance. J Gerontol. 1990;45: M192-M197.
226. Oldervoll LM, Loge JH, Paltiel H, et al. The effect of a physical exercise program in palliative care: a phase II study.J Pain Symptom Manage. 2006;31:421-430.
227. Berg K, Wood-Dauphinée SL, Williams J, Gayton D. Measuring balance in the elderly: preliminary development of an instrument. Physiother Can. 1989;4l:304-311.
228. Berg K, Maki B, Williams J, et al. Clinical and laboratory measures of postural balance in an elderly population. Arch Phys Med Rehabil. 1992;73:1073-1080.
229. Shumway-Cook A, Woollacott MH. Motor Control: Theory and Practical Applications. 2nd ed. Baltimore, MD: Lippin- cott Williams & Wilkins; 2001.
230. Whitney SL, Wrisley DM, Furman J. Concurrent validity of the Berg Balance Scale and the Dynamic Gait Index in people with vestibular dysfunction. Physiother Res Int. 2003;8:178-186.
231. Tinetti M. Tinetti performance-oriented mobility assessment in elderly patients. J Am Geriatr Soc. 1986;34:119-126.
232. Podsiadlo D, Richardson S. The timed "up and go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142-148.
233. Marchese VG, Chiarello L, Lange B. Effects of physical therapy intervention for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004;42: 127-133.
234. Deathe AB, Miller WC. The L Test of Functional Mobility measurement properties of a modified version of the Timed "Up & Go" Test designed for people with lower-extremity amputations. Phys Ther. 2005;85:626-635.
235. Davis A, Devlin M, Griffin A, et al. Functional outcome in amputation versus limb sparing of patients with lower extremity sarcoma; a matched case-control study Arch Phys Med Rehabil. 1999; 80:615-618.
236. Nagarajan R, Clohisy D, Neglia J, et al. Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma: the Childhood Cancer Survivor Study. Br J Cancer. 2004;91:1858-1865.
237. Rose DJ. Fall Proof! A Comprehensive Balance and Mobility Training Program. Champaign, IL; Human Kinetics Inc; 2003.
238. Dietz JC, Kartin D, Kopp K. Review of the Bruininks-Oseretsky Test of Motor Proficiency. Phys Occup Ther Pediatr. 2007;27:87-102.
239. Wright M, Halton J, Martin R, Barr R. Long-term gross motor performance following treatment for acute lymphoblastic leukemia. Med Pediatr Oncol. 1998;31:86-90.
240. Russell D, Rosenbaum P, Cadman D, et al, The Gross Motor Function Measure: a means to evaluate the effect of therapy. Dev Med Child Neurol. 1989;31: 341-352.
241. Palisano RJ, Kolobe TH, Haley SM, et al. Validity of the Peabody Developmental Gross Motor Scale as an evaluative measure of infants receiving physical therapy. Phys Ther. 1995;75:939-951.
242. MacLean WJ, Noll R, Stehbens J, et al; the Children's Cancer Group. Neuropsychological effects of cranial irradiation in young children with acute lymphoblastic leukemia 9 months after diagnosis. Arch Neurol. 1995;52:156-160.
243. Crisp J, Lingerer J, Goodnow J. The impact of experience on children's understanding of illness. J Pediatr Psychol. 1996;21:57-72.
244. Aass N, Fossa S. Pre- and post-treatment daily life function in patients with hormone-resistant prostate carcinoma treated with radiotherapy for spinal cord compression. Radiother Oncol. 2005; 74:259-265.
245. Bennett M, Ryall N. Using the modified Barthel index to estimate survival in cancer patients in hospice: observational study. BMJ. 2000;321:1381-1382.
246. Yoshioka H. Rehabilitation for the terminal cancer patient. Am J Phys Med Rehabil. 1994;73:199-206.
247. Osoba D, Aaronson N, Muller M, et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol. 1997;34:263-278.
248. Reuben D, Siu A. An objective measure of physical function of elderly outpatients. J Am Geriatr Soc. 1990;38:1105-1112.
249. Smith D, Ehde D, Hanley M. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. J Rehabil Res. 2005;42:645-654.
250. Huang M, Wartella J, Kreutzer J. Functional outcomes and quality of life in patients with brain tumor: a preliminary report. Arch Phys Med Rehabil. 2001; 82:1540-1546.
251. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45:2220-2224.
252. Bergner M, Bobbitt R, Carter W, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981;19:787-805.
253. De Bruin A, de Witte L, Stevens F, et al. Sickness Impact Profile: the state of the art of a generic functional status measure. Soc Sci Med. 1992;35:1003-1014.